Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer |
| |
Authors: | Kosei Yasumoto Takeshi Ogura |
| |
Affiliation: | (1) Respiratory Disease Center, Matsuyama Red Cross Hospital, Bunkyo-cho 1, 790 Matsuyama;(2) Third Department of Internal Medicine, School of Medicine, Tokushima University, Kuramoto-cho 3-18-15, 770 Tokushima, Japan |
| |
Abstract: | Forty-three patients with malignant pleurisy due to lung cancer were entered into the trial to evaluate clinical efficacy of intrapleural instillation of recombinant interleukin-2 (RIL-2). Among 35 evaluable patients, serial cytological examinations of pleural effusion following the start of the treatment revealed disappearance of malignant cells in 26 (74%). Malignant cells were detected again in 7 of the 26, however, cytology remained negative in the other 19 patients for longer than 4 weeks. Pleural effusion disappeared roentogenographically in 13 of 35 evaluable patients. Additional 8 patients demonstrated marked decrease of pleural effusion. Complete response (CR) which means disappearance of both malignant cells and pleural effusion for longer than 4 weeks was obtained in 13 of the 35 patients (37%). No serious side effects were experienced in this trial. These results indicate that intrapleural RIL-2 is one of candidates to control intractable malignant pleurisy due to lung cancer. |
| |
Keywords: | intrapleural RIL-2 lung cancer malignant pleurisy recombinant interleukin-2 (RIL-2) |
本文献已被 SpringerLink 等数据库收录! |
|